Signaturefd LLC Has $331,000 Position in Novartis AG (NVS)

Signaturefd LLC raised its position in shares of Novartis AG (NYSE:NVS) by 23.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,014 shares of the company’s stock after buying an additional 774 shares during the period. Signaturefd LLC’s holdings in Novartis AG were worth $331,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of NVS. Proficio Capital Partners LLC increased its stake in shares of Novartis AG by 4.3% in the second quarter. Proficio Capital Partners LLC now owns 24,371 shares of the company’s stock worth $2,000,000 after buying an additional 997 shares during the last quarter. SOL Capital Management CO increased its stake in shares of Novartis AG by 2.3% in the second quarter. SOL Capital Management CO now owns 4,495 shares of the company’s stock worth $371,000 after buying an additional 100 shares during the last quarter. GW Henssler & Associates Ltd. increased its stake in shares of Novartis AG by 12.9% in the second quarter. GW Henssler & Associates Ltd. now owns 54,479 shares of the company’s stock worth $4,495,000 after buying an additional 6,228 shares during the last quarter. Roberts Glore & Co. Inc. IL increased its stake in shares of Novartis AG by 1.6% in the second quarter. Roberts Glore & Co. Inc. IL now owns 13,065 shares of the company’s stock worth $1,078,000 after buying an additional 200 shares during the last quarter. Finally, Concert Wealth Management Inc. increased its stake in shares of Novartis AG by 5.4% in the second quarter. Concert Wealth Management Inc. now owns 9,186 shares of the company’s stock worth $759,000 after buying an additional 467 shares during the last quarter. 9.77% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Novartis AG (NYSE:NVS) traded down 0.86% during midday trading on Wednesday, reaching $75.65. The company had a trading volume of 1,569,570 shares. The company has a market capitalization of $180.14 billion, a price-to-earnings ratio of 27.01 and a beta of 0.57. The firm has a 50-day moving average price of $79.12 and a 200-day moving average price of $79.12. Novartis AG has a 52 week low of $69.90 and a 52 week high of $93.58.

Novartis AG (NYSE:NVS) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.18 by $0.05. Novartis AG had a net margin of 13.84% and a return on equity of 15.33%. The company earned $12.47 billion during the quarter, compared to analyst estimates of $12.33 billion. During the same period in the previous year, the business earned $1.25 EPS. Analysts expect that Novartis AG will post $4.72 EPS for the current fiscal year.

A number of brokerages recently commented on NVS. Jefferies Group reaffirmed a “buy” rating on shares of Novartis AG in a research report on Sunday. JPMorgan Chase & Co. reissued a “buy” rating on shares of Novartis AG in a report on Monday, October 10th. Chardan Capital reduced their price objective on Novartis AG from $95.00 to $92.00 and set a “buy” rating for the company in a report on Monday, October 10th. TheStreet lowered Novartis AG from a “buy” rating to a “hold” rating in a report on Wednesday, September 28th. Finally, Zacks Investment Research lowered Novartis AG from a “hold” rating to a “sell” rating in a report on Wednesday, September 21st. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $91.33.

Novartis AG Company Profile

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

5 Day Chart for NYSE:NVS

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Michael Jordan Gains Ground on Getting His Name Back
Michael Jordan Gains Ground on Getting His Name Back
McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
GoPro Planning to Cut 200 Jobs
GoPro Planning to Cut 200 Jobs
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Retailers Anticipating Strong Support for Small Business Saturday
Retailers Anticipating Strong Support for Small Business Saturday


 
© 2006-2016 Ticker Report. Google+.